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Abstract
Background: Tumor suppressor genes p53 and p16INK4a and the proto-oncogene MDM2 are considered to be essential 
G1 cell cycle regulatory genes whose loss of function is associated with ESCC carcinogenesis. We assessed the aberrant 
methylation of the p16 gene and its impact on p16INK4a protein expression and correlations with p53 and MDM2 protein 
expressions in patients with ESCC in the Golestan province of northeastern Iran in which ESCC has the highest 
incidence of cancer, well above the world average.
Methods: Cancerous tissues and the adjacent normal tissue obtained from 50 ESCC patients were assessed with 
Methylation-Specific-PCR to examine the methylation status of p16. The expression of p16, p53 and MDM2 proteins was 
detected by immunohistochemical staining.
Results: Abnormal expression of p16 and p53, but not MDM2, was significantly higher in the tumoral tissue. p53 was 
concomitantly accumulated in ESCC tumor along with MDM2 overexpression and p16 negative expression. Aberrant 
methylation of the p16INK4a gene was detected in 31/50 (62%) of esophageal tumor samples, while two of the adjacent 
normal mucosa were methylated (P < 0.001). p16INK4a aberrant methylation was significantly associated with decreased 
p16 protein expression (P = 0.033), as well as the overexpression of p53 (P = 0.020).
Conclusions: p16 hypermethylation is the principal mechanism of p16 protein underexpression and plays an 
important role in ESCC development. It is associated with p53 protein overexpression and may influence the 
accumulation of abnormally expressed proteins in p53-MDM2 and p16-Rb pathways, suggesting a possible cross-talk of 
the involved pathways in ESCC development.
Background
Esophageal cancer is the fifth leading cause of cancer-
related deaths in Iran [1]. It is also considered the second
most common type of cancer in both males and females
in Golestan province of northeastern Iran (Age Standard-
ized Rate: 22.57 in males and 19.89 in females in 105 per-
sons/year) (unpublished data). This region is located in
the "Esophageal Cancer Belt," stretching from China
westward through central Asia to northern Iran, where
there is a high incidence of Esophageal Squamous Cell
Carcinoma (ESCC)[2,3]. Although several environmen-
tal risk factors are proposed for ESCC, the specific under-
lying genetic alterations have not been well defined for
this region to date [3,4].
Several genetic and epigenetic alterations are involved
in esophageal carcinogenesis [5-7]. Investigation of alter-
ations in oncogenes and tumor suppressor genes impli-
cated in esophageal tumorigenesis may provide
molecular markers for early diagnosis and therapeutic
intervention[8].
Tumor suppressor genes P53  and  p16INK4a  and the
proto-oncogene MDM2 (Murine Double Minute 2), are
considered to be essential G1 cell cycle regulatory genes
and whose loss of function is associated with cancer
development [9].
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In response to DNA damage, p53 protein induces G1
cell cycle arrest or apoptosis [10]. Abnormalities of this
gene, such as gene mutation, can lead to the loss of regu-
lation of cell growth, DNA repair, or apoptosis, all of
which are responsible for carcinogenesis [11]. The prod-
uct of the MDM2 gene, which is induced by p53, appears
to play a critical role in regulating the level of the wild-
type p53 protein. It can bind to and inactivate the tran-
scriptional activity of p53, resulting in the abrogation of
p53 anti-proliferative and apoptotic effects, and conse-
quently the deregulation of cell overgrowth, which leads
to tumor development [11-13]. Acting as a cyclin-depen-
dent kinase inhibitor (CDKI), p16INK4a binds to and inhib-
its the activity of CDK4 and CDK6 and arrests the cell
cycle in the G1/S phase in a p53-dependent pathway
[14,15].
DNA methylation in the normally unmethylated pro-
moter region of tumor suppressor genes, such as
p16INK4a, is a critical mechanism for their inactivation
and is commonly associated with the repression of gene
transcription which promotes the development of can-
cers, including ESCC carcinogenesis [16-18]. Previous
reports from Iran showed that p16 hypermethylation in
the promoter region is a common mechanism for the
i n a c t i v a t i o n  o f  t h i s  g e n e  i n  E S C C  a n d  g a s t r i c  c a n c e r
development in Khorasan province of northeastern Iran
[19,20]. Aberrant p16 hypermethylation is also suggested
as a possible epigenetic risk factor in familial ESCC [21].
In addition, p53 alterations, including the mutation of
p53, have been identified as a frequent event in ESCC
development in northeastern Iran [22,23].
In the present study, we examined the methylation sta-
tus of the p16 gene, in 50 ESCC patients using Methyla-
tion Specific PCR (MSP) assay. p16,  p53  and  MDM2
protein expression was assessed to identify the associa-
tion of p16INK4a gene methylation with the expression of
these cell cycle proteins in a population with a high inci-
dence of ESCC in northeastern Iran.
Methods
Study population and sample collection
A total of 50 ESCC patients (ages ranging from 35-83
years) were recruited from May 2006 to June 2007, from
among patients referred to the two main referral oncol-
ogy centers in northeastern Iran: Atrak clinic, a referral
center for upper GI cancers in Golestan province, and
Omid Oncology Hospital, referral oncology hospital in
northeastern Iran. It is estimated that approximately 95%
of upper GI cancer patients in this region are referred to
Atrak clinic [24]. Patients did not receive any adjuvant
therapy (radiotherapy or chemotherapy) or blood trans-
fusions. Follow up carried out 6 to 24 months afterwards.
Demographic characteristics and information about
social habits, including the smoking or consumption of
cigarettes, the hookah and nass (a mixture of tobacco,
ash, and lime) [4], were obtained by trained interviewers
using a standard questionnaire. All patients underwent
upper GI endoscopy. Tissue samples of esophageal tumor
and macroscopically adjacent normal tissue from a site,
remote from the tumor, were dissected and fixed in 70%
alcohol and embedded in paraffin. The presence of nor-
mal and tumor tissue was assessed by histological evalua-
tion. The Research Ethics Committees of Tehran
University of Medical Sciences and Mashhad University
of Medical Sciences approved the study design. All eligi-
ble patients signed a written informed consent prior to
participating in the study.
DNA Extraction
Areas of the tumor in which tumor cells represented
>70% of all cells were extracted. Genomic DNA was
extracted from paraffin-embedded tissues by use of
xylene and alcohol. After digestion by proteinase K, DNA
was extracted and purified by the phenol/chloroform/iso-
amyl alcohol method and precipitated in ethanol, as pre-
viously described[20].
Bisulfite modification
Bisulfite modification of DNA results in conversion of
unmethylated cytosine residues into uracil, whereas, the
methylated cytosine residues, remains unchanged.
Briefly, 2 μg of DNA was denatured in 3 mol/L NaOH
(2 μL) for 10 min at 50°C and then modified by adding a
500 μl of a freshly prepared bisulfite solution (2.5 M
sodium bisulfate and 125 mM hydroquinone) following
to an incubation for 12 h at 50°C. DNA samples were
desalted through a column (Wizard DNA Clean-Up Sys-
tem, Promega), and then treated with 3 mol/L NaOH (5
μL) for 10 min at 37°C, followed by precipitation with 75
μl ammonium acetate (5 M). The pellet was washed with
2.5 volumes of ethanol, dried, and re-suspended in 20 μl
tris (pH 8.0, 5 mM), then stored at -70° until used for
MSP.
Methylation-Specific PCR (MSP)
After bisulfite treatment, DNA samples were assayed by
methylation-specific PCR. The PCR mixture was pre-
pared in a 25 μl volume containing 1× buffer (Finzymes,
Finland) with 2 mmol/L of MgCl2, 500 nmol/L of each
primer (previously described sequences[20]), 0.2 mmol/L
of dNTPs, 1 U of Hot Start Taq polymerase (Finzymes,
Finland), and bisulfite-modified DNA. DNA amplifica-
tion was performed in a thermocycler (Perkin-Elmer
Corp.). The PCR amplification consisted of an initial hot-
start step at 95°C for 10 min, followed by 40 cycles (45 s at
95°C, 45 s at 60°C, 60 s at 72°C), and a final 10 min exten-
sion at 72°C. Each MSP was repeated at least twice. In
addition to a negative control, DNA from L132 andTaghavi et al. BMC Cancer 2010, 10:138
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H1299 cells were used as a positive control for unmethy-
lated and methylated alleles, respectively. PCR products
were loaded on 2.5% agarose gel and 6% poly-acrylamide
gel, stained with silver nitrate dyes and visualized under
UV illumination.
Immunohistochemistry
Paraffin embedded sections (3 μm thick) of esophageal
tumor and adjacent normal tissue were used to perform
IHC reaction. Briefly, the sections were mounted on poly-
L-lysine-coated slides and dried at 60°C for 1 hour. The
sections were dewaxed and rehydrated in a xylene-etha-
nol series and boiled in the Target Retrieval Solution of
Dako (Dako, Carpinteria, CA, USA) in a microwave oven
for 40 min. After endogenous peroxidase blocking, the
following antibodies (Abs) were used: primary mouse
monoclonal  p16INK4a antibody (C-20) (Santa Cruz Bio-
technology, Santa Cruz, CA, USA) (IgG2a, 200 μg/ml) at
a working dilution of 1/1600, at 4°C overnight; mouse
anti-human p53 monoclonal antibody (clone: DO-7, iso-
type IgG2b) (Dako, Carpinteria, CA, USA), incubation
for 45 min at 37°C with a 1:50 dilution; and, for MDM2,
IgM mouse monoclonal clone 1B10 (carboxy terminus of
MDM2) was used (Novocastra Laboratories, New Castle,
UK) with a 1:100 dilution, incubated overnight. After two
w a s h e s  i n  P B S ,  s e c t i o n s  w e r e  i n c u b a t e d  w i t h  E n V i -
sionTM+System/HRP, Rabbit/Mouse (DAB+) (DakoCy-
tomation, Carpinteria, CA, USA), a secondary antibody.
The immunoreactivity was detected using diaminobenzi-
dine (DAB) (DakoCytomation, Carpinteria, CA, USA) as
the final chromogen. Finally, sections were counter-
stained with Meyer's Hematoxylin, dehydrated through a
sequence of increasing concentrations of alcoholic solu-
tions and cleared in xylene. During each IHC assay, proof
slides were coupled with negative control slides on which
the primary antibody was omitted. P16-positive and p53-
positive esophageal squamous cell carcinoma was used as
positive controls in every section. The cutoff values for
abnormal expression were determined as follows: MDM2
> 30% [25]; p53 > 5% [26]; p16 < 5% [9].
Statistical analysis
The Statistical Package for the Social Sciences software
version 16.0 (SPSS Inc., Chicago, IL, USA) was used for
statistical analyses. The correlation between two vari-
ables was evaluated using Pearson's chi-square and
Fisher's exact tests. Survival rates were calculated by the
Kaplan-Meier method. Using the log-rank test, we com-
pared the survival of ESCC patients according to various
clinicopathological factors. A 2-sided P value < 0.05 was
considered as the significant statistical level.
Results
Fifty ESCC patients (ages ranging from 35 to 83 years;
with the mean age of 59.02 ± 11.41 years) were enrolled in
this study. T wenty five (50%) patients were men and 25
were women with the male to female ratio of 1. T umor
sizes ranged from 2 to 12 cm, with a mean diameter was
4.97 ± 2.13 cm. Clinicopathological characteristics of the
ESCC patients are summarized in table 1.
The methylation status of 5' CpG island of the p16 gene
was detected in 31/50 (62%) esophageal tumor samples,
while two of the adjacent normal mucosa were methy-
lated (P < 0.001). No significant association was found
between the methylation status of the p16 gene and the
factors studied, including age, sex, tumor histopathology,
tumor site and size, and opium and tobacco use (cigarette
and hookah smoking, Nass chewing) (Table 1). Figure 1
represents MSP analysis of p16 gene.
Immunohistochemical staining
IHC staining of p16, p53 and MDM2 are represented in
figure 2.
a) Immunohistochemical staining of p16, p53 and MDM2
The negative expression of the p16 protein was detected
in 28/50 (56%) tumors and only 7/50 (14%) normal tissues
(P < 0.001).
The positive expression of p53 and MDM2 proteins in
the nuclei was detected in 31/50 (62%) and 21/50 (42%)
tumor tissues and in 7/50 (14%) and 30/50 (60%) normal
esophageal tissues, respectively. There was a significant
difference between tumor and normal tissues for p53
staining (P = 0.001), but not for MDM2. The histological
grade of differentiation was not associated with the IHC
staining of p16, p53 and MDM2.
b) Concomitant p16, p53 and MDM2 protein expression in 
ESCC
The overexpression of MDM2 was not significantly asso-
ciated with the abnormal expression of p53. There was
neither significant correlation between p16 and p53, nor
between p16 and MDM2 immunoreactivity in esophageal
tumor and normal samples, independently. Concomitant
abnormal accumulation of the p53  protein with either
MDM2 overexpression or abnormal underexpression of
p16  was significantly more frequent in tumoral tissue
compared to normal tissue; p16-/p53+ immunostaining
was detected in 20/50 (40%) tumors and in none of the
normal tissues; whereas the opposite combination (p16+/
p53-) was found in 11/50 (22%) tumors and 36/50 (72%)
normal specimens, with a statistically significant differ-
ence between tumor and normal samples in these sub-
groups (P < 0.001). In tumoral and normal tissues, the
proportion of p53+/MDM2+ was 16/50 (32%) and 2/50
(4%), while p53-/MDM2-  was detected in 14/50 (28%)
and 14/50 (28%) respectively, with a statistically signifi-
cant difference (P < 0.001). On the other hand, with
MDM2+/p16-, there was not a significant difference in
tumors compared to normal tissues (P = 0.078).
We also investigated the association between the p16/
p53/MDM2 profile and tobacco use, histology of tumor,Taghavi et al. BMC Cancer 2010, 10:138
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and p16 methylation status in ESCC. The samples were
divided into four groups according to the number of
alterations detected. The p16-/p53+/MDM2+ immuno-
profile was only observed in the tumor tissues and not in
the normal adjacent tissue (P < 0.001). Similarly we
observed this profile more frequently in p16-methylated
tumors (P = 0.035). We did not find any significant asso-
ciation between tobacco consumption and different his-
tological subtypes with the different immunoprofiles.
(Table 2)
Correlation between p16, p53 and MDM2 
immunoreactivity, and hypermethylation of p16
Twenty one out of thirty one (67.7%) methylation-posi-
tive esophageal tumors showed a complete lack of immu-
noreactivity of p16. Twelve out of nineteen (63.2%) of
unmethylated tumors represented diffuse immunoreac-
tivity, whereas 7/19 (36.8%) of unmethylated tumors were
not immunostained for p16. p16 negative staining was
significantly correlated with p16 methylation (P = 0.033).
Significant association was observed between abnormal
accumulation of p53  and  p16  hypermethylation (p =
0.020). Moreover, p16 methylation was more frequent in
cases with concomitant accumulation of p53 and loss of
p16 proteins i.e. 17/20 (85%), compared to the cases with
p16 expressed and p53 negative, 4/11 (36.36%) (P = 0.01).
p16 methylation was not associated with MDM2 overex-
pression. (Table 1)
Patients' Survival
The 6-months, 1- year, and 2-year survival rates were
78%, 43%, and 28% in tumors with p16 hypermethylation
and 43%, 14%, and 0% in tumors without p16 hypermeth-
ylation, respectively. The median survival duration of
patients with p16  hypermethylation was 8 months,
whereas it was 5 months for patients without hypermeth-
Table 1: Distribution of p16 methylation status according to clinicopathological features and protein expressions in ESCC 
tumors
Number (%) methylated unmethylated p value
Age
<60 25 (54.3) 16 (59.3) 9 (47.4) 0.421
≥60 21 (45.7) 11 (40.7) 10 (52.6)
Gender
Male 25 (50) 15 (48.4) 10 (52.6) 0.773
Female 25 (50) 16 (51.6) 9 (47.4)
Histology
Well 25 (55.6) 15 (33.3) 10 (22.2) 0.211
Moderate 13 (28.9) 9 (20.0) 4 (8.8)
Poor 7 (15.6) 2 (4.4) 5 (11.1)
Tumor site
Upper 1 (2.8) 0 (0.0) 1 (5.9) 0.854
Middle 23 (63.9) 12 (63.2) 11 (64.7)
Lower 12 (33.3) 7 (36.8) 5 (29.4)
Tobacco use
Positive 14 (30.4) 8 (29.6) 6 (31.6) 0.896
Negative 32 (69.6) 19 (70.4) 13 (68.4)
p16 protein
Positive 22 (44) 10 (32.3) 12 (63.2) 0.033
Negative 28 (56) 21 (67.7) 7 (36.8)
p53 protein
Positive 31 (62) 23 (74.2) 8 (42.1) 0.020
Negative 19 (38) 8 (25.8) 11 (57.9)
MDM2 protein
Positive 21 (42) 16 (51.6) 5 (26.3) 0.080
Negative 29 (58) 15 (48.4) 14 (73.7)Taghavi et al. BMC Cancer 2010, 10:138
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ylation. The 6 months, 1-year, and 2-year survival rates
were 67%, 33%, and 33% in cases with p16 expression
group and 62%, 31% and 18% in the cases with loss of p16,
respectively. The median survival duration of patients
with and without loss of p16 expression was 8 and 10
months, respectively.
There was no statistically significant difference in sur-
vival rates based on the p16 hypermethylation status or
p16 protein expression.
Discussion
Golestan province in northeastern Iran has a high inci-
dence of ESCC, which is well above the world average. To
better understand some aspects of the complex genetic/
epigenetic alterations in this high incidence region, we
investigated the role of some components of p53-MDM2
and p16-Rb pathways of cell cycle regulation and their
possible cross-talk in ESCC tumorigenesis. Thus, we
assessed p16 hypermethylation as an important mecha-
nism of gene silencing, its impact on the p16  protein
expression, along with its correlation with the p53 and
MDM2 protein expression.
We showed that p16  protein expression was signifi-
cantly associated with methylation of the p16 gene, indi-
cating that p16 methylation may play a critical role in the
silencing of this important tumor suppressor gene. On
the other hand, significant differences in both methyla-
tion and loss of protein expression of p16 in tumoral tis-
sue compared to the normal tissue confirms the critical
role of these genetic and epigenetic alterations in the
development of ESCC in this high-incidence region. In
this study, p16 hypermethylation was observed in 62% of
the patients. Previous reports of p16 methylation varied
between 40-90% among ESCC patients in the Far East.
Xing et al [27] studied 40 ESCC patients and detected the
p16  gene hypermethylation in 40% of tumor samples.
Whereas, Hardie et al [28] and Hibi et al [29] reported
promoter methylation of the p16 gene in 85% (18/21) and
82% (31/38) of esophageal carcinoma, respectively. Wang
Figure 1 MSP analysis of p16 gene in ESCC patients. DNA from H1299 cells served as a positive control for hypermethylated DNA and L132 as a 
positive control for unmethylated DNA. Patient 17 (p17) and patient 25 (p25) were hypermethylated, which revealed 150 bp bands (M) with hyperm-
ethylated primers. Patient 12 (p12) and patient 9 (p9) were not methylated, having only unmethylated band (U).
Figure 2 Typical images of Immunohistochemical staining. a) Pos-
itive p16 immunoreactivity. b) Negative p16 immunoreactivity c) Over-
expression of p53 protein. d) Negative p53 immunostaining e) 
Overexpression of MDM2 protein. f) Negative MDM2 immunoreactivi-
ty.Taghavi et al. BMC Cancer 2010, 10:138
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et al [30] showed the aberrant hypermethylation of p16,
as a frequent event, in 88% of ESCC patients in China.
Abbaszadegan et al reported 73.3% p16 gene methylation
in ESCC samples in Khorasan, another province in the
northeastern Iran. In support of their data, this study
indicates the critical role of p16  methylation in ESCC
development in this high risk region [19].
In this study, we also examined p16 methylation in nor-
mal tissue adjacent to tumor, in order to clarify whether
p16  methylation may have been occurred in the back-
ground of tumors. We showed that in two ESCC patients,
p16 methylation occurred not only in the tumoral cells
but also in the corresponding normal tissue. In the nor-
mal tissue of one of the two, p16  protein was not
expressed. In line with our data on p16 methylation in
normal tissue, Hibi et al presented one case of p16 meth-
y l a t i o n  i n  t h e  n o r m a l  t i s s u e  i n  a d d i t i o n  t o  W B C s  o f
peripheral blood. They suggested that individuals with
p16  promoter methylation of normal tissue might be
prone to development of cancer. Furthermore, other
studies have provided evidence of p16  methylation in
normal tissue. p16 methylation of normal tissues, as a
rare event, was also shown by Esteller et al [31]. Guan et
al [32]reported the p16  methylation of transitional
mucosa in 2/8 colon cancer patients. We can speculate
that the presence of p16 methylation in normal tissue of
these two studied ESCC patients may prone them to trig-
ger tumor formation in these tissues. Although p16
hypermethylation most often occurs in the late preneo-
plastic stages (i.e. dysplasia) [33], it seems that in a small
proportion of individuals, methylation may rarely occur
in the normal tissue of esophagus. Environmental factors,
previously reported as influencing aberrant hypermethy-
lation, such as exposure to carcinogens or dietary factors,
[34-37], along with a possible genetic predisposition, such
as DNA methyltransferase activation [38], may be
responsible for the epigenetic alterations and methylation
induction in the normal tissue of this small proportion.
However, further large-scale studies are required to focus
on this issue and validate the probable impact of life-style
and environmental factors and possible genetic predispo-
sitions on the methylation status of normal esophageal
tissue.
Regarding  p16  immunostaining, we did not detect
hypermethylation in 7 out of 28 ESCC tumor tissues
(25%) with negative p16 immunostaining. This suggested
that other molecular mechanisms, such as point muta-
tion, homozygous deletion or loss of heterozygosity, may
contribute to p16  gene inactivation [39-41]. In 20% of
ESCCs (10/50), p16 protein expression was accompanied
by positive p16 hypermethylation. This can possibly be
explained by hemi-methylation of the p16 gene. It may
Table 2: Correlation of p16/p53/MDM2 immunoprofile in ESCC patients with p16 methylation and clinicopathological 
features
Alteration
abcd p  v a l u e
p16 methylation
Positive 3 (33.3) 6 (46.2) 12 (70.6) 10 (90.9) 0.028
Negative 6 (66.7) 7 (53.8) 5 (29.4) 1 (9.1)
Tobacco use
Positive 2 (22.2) 7 (58.3) 3 (21.4) 2 (18.2) 0.145
Negative 7 (77.8) 5 (41.7) 11 (78.6) 9 (81.8)
Histology
Well 3 (33.3) 7(53.8) 6 (50) 9 (81.8) 0.173
Moderate 2 (22.2) 4 (30.8) 5 (41.7) 2 (18.2)
Poor 4 (44.4) 2 (15.4) 1 (8.3) 0 (0.0)
Tissue
Tumor 9 (56.2) 13 (43.4) 17 (80.9) 11 (100) 0.001
Normal 7 (43.8) 17 (56.6) 4 (19.1) 0 (0.0)
a p16+/p53-/MDM2- profile
bp16-/p53-/MDM2- profile or p16+/p53+/MDM2- profile or p16+/p53-/MDM2+ profile
cp16-/p53+/MDM2- profile or p16-/p53-/MDM2+ profile or p16+/p53+/MDM2+ profile
dp16-/p53+/MDM2+ profileTaghavi et al. BMC Cancer 2010, 10:138
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also reflect the high sensitivity of the MSP method, i.e.
0.1% methylated DNA, which would indicate that tumor
samples with a low proportion of methylated DNA could
be considered as methylation positive by MSP even
though they may withhold p16 immunoreactivity due to
unmethylated tumor cells in the same sample [42].
It has been hypothesized that p53 alterations may con-
comitantly occur with alterations in p16INK4a in carcino-
genesis [43]. As for the p53-MDM2 pathway, when the
p16 methylation status was compared with the p53 and
MDM2 protein expression in ESCC patients, we observed
that ESCC tumors with p16 epigenetic inactivation more
often harbored increased levels of p53 protein expression.
T o our knowledge, this is the first report indicating the
association between p16 hypermethylation and p53 pro-
tein accumulation in ESCC. Lee et al detected abnormal
accumulation of p53, along with p16 promoter hyperm-
ethylation in colon cancer despite the inverse correlation
between them as reported by other previous studies [44].
Esteller et al showed that p53 overexpression was inde-
pendent of p16 methylation status in colorectal cancer
[45]. Ishii et al reported more extensive DNA methylation
in neoplastic lesions of ESCC with a p53 mutation than in
those with wild-type p53, when assessing the promoter
hypermethylation of 14 tumor suppressor genes; however
p16 hypermethylation was not independently associated
with p53 mutation[46].
These observations may help us address the occurrence
of combined molecular mechanisms, which are likely to
play a major role in ESCC tumor progression. Since cell
populations of the primary neoplasm are heterogeneous,
a single marker cannot specifically and accurately predict
the behavior of the tumor [47]. Abnormal p53 expression
occurs concomitantly with abnormally expressed p16 or
MDM2 proteins in the tumor. On the other hand, p16
hypermethylation is associated with a larger accumula-
tion of abnormal protein expression in both p16-Rb and
p53-MDM2 pathways. All these findings in addition to
correlation between p16  hypermethylation and p53
abnormal accumulation, indicate a possible overlap and
cross-talk between the involved pathways.
Although it has been reported that p16 hypermethyla-
tion is a predisposing epigenetic trait in the familial ESCC
in Iran [21], the role of other factors such as environmen-
tal factors has not yet been ruled out. It has been
reported that high-level exposure to polycyclic aromatic
hydrocarbons may contribute to the high incidence of
E S C C  i n  t h e  n o r t h e a s t e r n  I r a n  [ 4 ] .  C o n c o m i t a n t  p16
hypermethylation and p53 overexpression may be a con-
sequence of various environmental, dietary or lifestyle
factors peculiar to this region, associated with an
increased susceptibility to ESCC. However due to the
lack of a precise evaluation of environmental exposures in
this study, we could not strongly deduce any correlation
between these factors and p16  methylation or protein
expression status, as well as p53 and MDM2 overexpres-
sion.
Conclusion
In summary, we conclude that p16 gene silencing caused
by hypermethylation of CpG islands may be a major
m e c h a n i s m  i n  t h e  E S C C  d ev e l o p m e n t.  I t  i s  as s oc i a t ed
with p53 protein overexpression in the ESCC patients of
northeastern Iran. This is the first study indicating the
association between p16 hypermethylation and p53 pro-
tein overexpression. The impact of p16 hypermethylation
on accumulation of abnormally expressed proteins in the
p53-MDM2 pathway, along with the observed concomi-
tant accumulation of p53 with either MDM2 overexpres-
sion or decreased p16  expression, suggests a possible
cross-talk of the involved pathways in ESCC development
in northeastern Iran. Further studies of the methylation
status of various cancer-related genes in a large sample
size, accompanied by the assessment of exposure to the
potentially harmful environmental factors, are needed to
better elucidate the genetic changes occurring in ESCC
carcinogenesis and tumor progression in this high risk
population.
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